USANA Health Sciences (NYSE:USNA) Reaches New 12-Month Low – Here’s What Happened

USANA Health Sciences, Inc. (NYSE:USNA) reached a new 52-week low during trading on Tuesday . The company traded as low as $27.58 and last traded at $28.03, with a volume of 59771 shares changing hands. The stock had previously closed at $27.98.

Analyst Upgrades and Downgrades

USNA has been the topic of a number of recent analyst reports. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. DA Davidson reduced their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Finally, Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th.

USANA Health Sciences Trading Up 0.7 %

The firm’s 50 day moving average is $32.39 and its two-hundred day moving average is $35.78. The stock has a market cap of $532.84 million, a price-to-earnings ratio of 9.94, a P/E/G ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The business had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. As a group, equities analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Joshua Foukas sold 5,732 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jim Brown sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the sale, the chief executive officer now directly owns 15,716 shares of the company’s stock, valued at approximately $463,150.52. This represents a 24.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,920 shares of company stock valued at $500,285 over the last three months. Company insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its holdings in shares of USANA Health Sciences by 111.9% during the 3rd quarter. Barclays PLC now owns 27,737 shares of the company’s stock worth $1,052,000 after purchasing an additional 14,647 shares in the last quarter. Rhumbline Advisers increased its stake in shares of USANA Health Sciences by 39.8% in the 4th quarter. Rhumbline Advisers now owns 49,390 shares of the company’s stock valued at $1,773,000 after buying an additional 14,068 shares during the period. Principal Financial Group Inc. grew its stake in shares of USANA Health Sciences by 2.8% during the fourth quarter. Principal Financial Group Inc. now owns 53,603 shares of the company’s stock worth $1,924,000 after purchasing an additional 1,480 shares during the period. Pzena Investment Management LLC grew its stake in shares of USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company’s stock worth $39,015,000 after purchasing an additional 37,466 shares during the period. Finally, Geode Capital Management LLC grew its stake in USANA Health Sciences by 4.5% in the third quarter. Geode Capital Management LLC now owns 297,120 shares of the company’s stock valued at $11,269,000 after acquiring an additional 12,898 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.